Oncology Venture A/S Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
|
24/05 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
14/05 | Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 77.7L 8.15Cr 65Cr |
---|---|---|---|---|---|
Net income 2024 * | -1.6Cr -17Cr -133.76Cr | Net income 2025 * | -2.8Cr -29Cr -234.08Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-0.29
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Latest transcript on Oncology Venture A/S
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 01/20/01 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21/21/21 |
Chief Tech/Sci/R&D Officer | 63 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 56 | 01/22/01 | |
Thomas Jensen
FOU | Founder | 46 | 01/20/01 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 01/23/01 |
1st Jan change | Capi. | |
---|---|---|
+15.85% | 12TCr | |
+18.91% | 11TCr | |
+4.43% | 2.26TCr | |
-18.63% | 2.08TCr | |
-13.76% | 1.63TCr | |
-16.61% | 1.62TCr | |
-43.53% | 1.62TCr | |
+1.75% | 1.32TCr | |
+28.07% | 1.11TCr |